ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 897 • 2012 ACR/ARHP Annual Meeting

    IL-33 Promotes Mast Cell Survivial Via Inhibition of Apoptosis Associated with Enhanced Expression of Bcl-XL

    Shinjiro Kaieda1, Jun-Xia Wang2 and Peter A. Nigrovic3, 1Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, 2Department of Medicine, *Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Mast cells (MCs) are potent innate immune cells that frequently accumulate in chronically inflamed tissues, including the arthritic synovium. The factors that regulate MC…
  • Abstract Number: 898 • 2012 ACR/ARHP Annual Meeting

    Nuclear Receptor Related 1 Induces Synovial Hyperplasia Via Transcriptional Regulation of Novel Target Genes

    Kimberlee S. Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA

    Background/Purpose: Nuclear receptor related 1 (NURR1 / NR4A2) is an orphan member of the nuclear receptor super-family that functions as a constitutively active transcription factor.…
  • Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting

    A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling

    Misato Hashizume1, Keiko Esaki2 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

    Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
  • Abstract Number: 900 • 2012 ACR/ARHP Annual Meeting

    Deletion of RBP-J in a Murine Model of Inflammatory Arthritis Reveals Differential Pro-Inflammatory Cytokine and FoxP3 Gene Expression

    Soumya D. Chakravarty1, Karmen Au2, Xiaoyu Hu3 and Lionel B. Ivashkiv4, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Arthritis Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, 4Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

    Background/Purpose: The DNA-binding protein RBP-J serves as the central transcriptional regulator of the Notch signaling pathway. Prior work done using a knockdown approach of RBP-J…
  • Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting

    Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis

    Samuel Garcia1, Linda M. Hartkamp2, Inge E. van Es2, Haishan Lin3, Li Long3, Emma L. Masteller3, Brian R. Wong3, Paul P. Tak4 and Kris A. Reedquist2, 1Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 3Five Prime Therapeutics, Inc., South San Francisco, CA, 4Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands

    Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
  • Abstract Number: 902 • 2012 ACR/ARHP Annual Meeting

    Activation of NF-Kb Via Poly(I:C)-Induced Monocyte-Derived Microparticles Decreases TRAIL-Induced Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts

    Mojca Frank Bertoncelj1, Blaz Rozman2, Beat A. Michel3, Renate E. Gay1, David S. Pisetsky4, Oliver Distler5, Steffen Gay6 and Astrid Juengel7, 1Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 2Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Department of Medicine, Duke University Medical Center, Durham, NC, 5Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, CH-8091, Switzerland, 7Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland

    Background/Purpose: Decreased sensitivity of rheumatoid arthritis (RA) synovial fibroblasts (SF) to apoptosis leads to synovial hyperplasia and destruction of joints in RA. Activation of NF-kB…
  • Abstract Number: 903 • 2012 ACR/ARHP Annual Meeting

    NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic Cells

    Natacha Ipseiz1, Stefan Uderhardt1, Georg A. Schett2 and Gerhard Kronke1, 1Internal Medicine 3, University of Erlangen, Erlangen, Germany, 2Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: The nuclear receptor NR4A1 has been implicated as negative feedback regulator of NF kappa B signalling and as key regulator during the differentiation of…
  • Abstract Number: 904 • 2012 ACR/ARHP Annual Meeting

    Perinatal Characteristics, Maternal Reproductive History and Juvenile Idiopathic Arthritis: A Case-Control Study

    Samantha W. Bell1, Beth A. Mueller1, J. Lee Nelson2, Parveen Bhatti1 and Susan Shenoi3, 1Epidemiology and Public Health, University of Washington, Seattle, WA, 2Immunogenetics D2-100, Fred Hutchinson Cancer Rsch, Seattle, WA, 3Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritis conditions in children with onset before 16 years of age, and is the…
  • Abstract Number: 905 • 2012 ACR/ARHP Annual Meeting

    The Association Between Lower Body Mass Index and Increased Risk of Giant Cell Arteritis Is Not Explained by Differences in Physical Activity

    Karin Jakobsson1, Lennart T.H. Jacobsson1, Kenneth J. Warrington2, Eric L. Matteson3, Kimberly P. Liang4, Olle Melander5 and Carl Turesson1, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Division of Rheumatology, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Unit of Hypertension and Cardiovascular Disease, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: There is limited data on predictors of giant cell arteritis (GCA). Low body mass index (BMI), a history of smoking and several hormonal factors…
  • Abstract Number: 906 • 2012 ACR/ARHP Annual Meeting

    Patient-Rheumatologist Communication Concerning Medication and Disease Risks

    Susan J. Blalock, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Medications play an important role in the management of rheumatoid arthritis.  Principles of informed consent, informed and shared decision-making, and professional ethics highlight the importance…
  • Abstract Number: 907 • 2012 ACR/ARHP Annual Meeting

    Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis

    Liana Fraenkel1, Charles Cunningham2, Gillian A. Hawker3 and Lisa Suter4, 1Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 2McMaster University, Hamilton, ON, Canada, 3Women's College Research Institute, University of Toronto, Toronto, ON, Canada, 4Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT

    Background/Purpose: Considerable efforts are currently being directed at developing robust and efficient trial designs to study the efficacy of disease modifying drugs (DMOADs) for osteoarthritis…
  • Abstract Number: 908 • 2012 ACR/ARHP Annual Meeting

    Race, Gender and Total Knee Replacement Consideration: The Role of Social Support

    Ernest R. Vina1, Yona Cloonan2, Said Ibrahim3, Michael J. Hannon4, Robert M. Boudreau5 and C. Kent Kwoh6, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 2Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, 3Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Epidemiology, University of Pittsburgh, Pittsburgh, PA, 6School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: There is marked variation in patient preference (i.e. willingness) regarding total knee replacement (TKR), an effective treatment option for end-stage osteoarthritis (OA).  Studies have…
  • Abstract Number: 909 • 2012 ACR/ARHP Annual Meeting

    Determinants of Patient Preferences for Total Knee Replacement: A Comparison of Whites and African-Americans

    C. Kent Kwoh1, Robert M. Boudreau2, Yona Cloonan3, Michael J. Hannon4, Ernest R. Vina5 and Said Ibrahim6, 1School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology, University of Pittsburgh, Pittsburgh, PA, 3Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, 4Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, 6Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: TKR is a cost-effective treatment option for end-stage knee osteoarthritis (OA). Although it is one of the fastest growing elective surgeries, there are marked…
  • Abstract Number: 910 • 2012 ACR/ARHP Annual Meeting

    The Cost-Effectiveness of Total Joint Arthroplasty: A Systematic Review of Published Literature

    Meghan E. Daigle1, Alexander M. Weinstein1, Jeffrey N. Katz2 and Elena Losina1, 1Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Utilization of total hip arthroplasty (THA) and total knee arthroplasty (TKA) has nearly doubled in the last decade.  These procedures are increasingly performed in…
  • Abstract Number: 911 • 2012 ACR/ARHP Annual Meeting

    Race- and Sex-Specific Estimates of 10-, 20-, 30-Year, and Lifetime Risk of Diagnosed Symptomatic Knee Osteoarthritis and the Need for TKR in the US

    Elena Losina1, Meghan E. Daigle1, Sara A. Burbine1 and Jeffrey N. Katz2, 1Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A growing body of evidence suggests that females are more likely to be diagnosed with knee osteoarthritis (OA) and that obesity increases the risk…
  • « Previous Page
  • 1
  • …
  • 2541
  • 2542
  • 2543
  • 2544
  • 2545
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology